Stockscreener 앱 받기
18.01
8.53%
-1.68
시간 외 거래:
18.01
전일 마감가:
$19.69
열려 있는:
$19.27
하루 거래량:
123.63K
Relative Volume:
2.94
시가총액:
$541.70M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-17.76%
1개월 성능:
-7.74%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$17.20
$20.85
1주일 범위
$17.20
$22.56
52주 변동 폭
$17.04
$24.03
Evommune Inc Stock (EVMN) Company Profile
명칭
Evommune Inc
전화
(650) 223-7745
주소
1841 PAGE MILL RD, PALO ALTO
EVMN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EVMN
Evommune Inc
|
18.01 | 592.23M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Evommune Inc Stock (EVMN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-12-01 | 개시 | Evercore ISI | Outperform |
| 2025-12-01 | 개시 | Leerink Partners | Outperform |
| 2025-12-01 | 개시 | Morgan Stanley | Overweight |
| 2025-12-01 | 개시 | William Blair | Outperform |
Evommune Inc 주식(EVMN)의 최신 뉴스
These Bay Area companies are IPO contenders in 2026 - The Business Journals
Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update - BioSpace
Evommune, Inc.: Promising Pipeline and Strategic Trials Drive Buy Rating - TipRanks
Evommune, Inc. SEC 10-Q Report - TradingView — Track All Markets
EVMN: Net loss narrowed to $40.6M as license revenue grew and IPO proceeds extended cash runway into 2028 - TradingView — Track All Markets
Evommune (EVMN) Stock Trends and Sentiment 2025 - MarketBeat
Biopharma funding normalizes as 2025 outperforms post-pandemic lows - BioWorld MedTech
Evommune, Inc. (EVMN) analyst ratings, estimates and forecasts - Yahoo Finance UK
Evommune (NYSE:EVMN) Upgraded at Zacks Research - Defense World
Evommune (EVMN) Competitors and Alternatives 2025 - MarketBeat
Evommune (NYSE:EVMN) Research Coverage Started at Evercore ISI - Defense World
Evommune (NYSE:EVMN) Shares See Activity on Sector Research Shift - Kalkine Media
Evommune (NYSE:EVMN) Stock Rating Upgraded by Leerink Partnrs - MarketBeat
Evommune initiated with an Outperform at William Blair - MSN
Evommune initiated with an Overweight at Cantor Fitzgerald - MSN
Evommune, Inc. (EVMN) options chain - Yahoo Finance UK
Evommune, Inc.: Revenue and Earnings Analysts Forecasts Revisions | EVMN | US30054Y1073 - marketscreener.com
Evommune, Inc.: Target Price Consensus and Analysts Recommendations | EVMN | US30054Y1073 - marketscreener.com
Evommune, Inc.: Dividend historical data and projections - marketscreener.com
Evommune, Inc. (NYSE:EVMN) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Evommune (NYSE:EVMN) Coverage Initiated by Analysts at Leerink Partners - MarketBeat
Evommune initiated with an Overweight at Morgan Stanley - MSN
Evercore ISI initiates Evommune stock with Outperform rating on dermatology potential - Investing.com Australia
Evommune, Inc. (EVMN) Options Chain - Yahoo! Finance Canada
Leerink Partners initiates coverage on Evommune stock with Outperform rating By Investing.com - Investing.com South Africa
Evommune, Inc. (EVMN) Stock Forum & Discussion - Yahoo! Finance Canada
Cantor Fitzgerald initiates Evommune stock with Overweight rating By Investing.com - Investing.com South Africa
Evercore ISI initiates Evommune stock with Outperform rating on dermatology potential By Investing.com - Investing.com South Africa
Leerink Partners initiates coverage on Evommune stock with Outperform rating - Investing.com Nigeria
Evommune initiated with an Outperform at Evercore ISI - MSN
Evommune's Skin Disorder Candidate Has 'Blockbuster Commercial Opportunity': Analyst Projects $5 Billion Peak Sales - Benzinga
EVMN Analyst Forecasts - Quiver Quantitative
This Joby Aviation Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday - Benzinga
William Blair Initiates Coverage on Evommune With Outperform Rating - marketscreener.com
Evercore ISI Initiates Coverage on Evommune With Outperform Rating, $40 Price Target - marketscreener.com
Cantor Fitzgerald Initiates Coverage on Evommune With Overweight Rating - marketscreener.com
Cantor Fitzgerald initiates Evommune stock with Overweight rating - Investing.com
Leerink Partners Initiates Coverage on Evommune With Outperform Rating, $42 Price Target - marketscreener.com
Morgan Stanley Initiates Evommune at Overweight With $36 Price Target - marketscreener.com
William Blair initiates coverage on Evommune stock with Outperform rating By Investing.com - Investing.com South Africa
William Blair initiates coverage on Evommune stock with Outperform rating - Investing.com
Promising Outlook for Evommune’s EVO756: Buy Rating Backed by Strong Data and Market Potential - TipRanks
Promising Future for Evommune, Inc. in Inflammatory and Immunology Markets: Buy Rating Justified by Strong Pipeline and Experienced Leadership - TipRanks
Morgan Stanley initiates Evommune stock with Overweight rating on inflammation pipeline - Investing.com Australia
What is the current Price Target and Forecast for Evommune Inc. (EVMN) - Zacks Investment Research
Evommune Inc. (EVMN) Price Book Value - Zacks Investment Research
Why Is Evommune, Inc. (EVMN) Stock Up Today? - Meyka
EVMN: Evommune Inc.Price & Consenus Chart - Zacks Investment Research
Evommune Inc. (EVMN) Price To Cash Flow - Zacks Investment Research
Evommune Inc. (EVMN) Market Cap - Zacks Investment Research
Evommune Inc. (EVMN) Dividend Yield (TTM) - Zacks Investment Research
Evommune Inc (EVMN) 재무 분석
Evommune Inc (EVMN)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):